First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other Folate Receptor 1 (FOLR1)-Positive Solid Tumors

NCT01609556 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
206
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

ImmunoGen, Inc.